Even though evidence-based treatment for opioid use disorders (OUD) is effective, almost
four in five Americans with OUD do not receive any form of treatment. The gap in access to …

Background Opioid-related deaths have risen dramatically in rural communities. Prior
studies highlight few medication treatment providers for opioid use disorder in rural …

The opioid crisis in the United States has come about because of excessive use of these
drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use …

Objectives. We estimated national and state trends in opioid agonist medication-assisted
treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions …

Background RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a
subcutaneously injected, monthly buprenorphine treatment for opioid use disorder. BUP-XR …

PURPOSE The United States is experiencing an epidemic of opioid-related deaths driven by
excessive prescribing of opioids, misuse of prescription drugs, and increased use of heroin …

Background Despite evidence that medications to treat opioid use disorder (OUD) are
effective, most people who could benefit from this treatment do not receive it. This rapid …

At least 2.3 million people in the US have an opioid use disorder, less than 40% of whom
receive evidence-based treatment. Buprenorphine used as part of medication-assisted …

Abstract Background Between 2012 and 2017, the United States dramatically reduced
opioid prescribing rates. While this may be appropriate given the opioid epidemic, there has …

Background The opioid epidemic is a public health crisis. Medications for opioid use
disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release …